References
- Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 2007;68(19):1571–5. doi:https://doi.org/10.1212/01.wnl.0000260965.20021.47. Cited in: PubMed; PMID: 17485643.
- Marin B, Boumediene F, Logroscino G, Couratier P, Babron M. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol 2017;46(1):57–74. doi:https://doi.org/10.1093/ije/dyw061. Cited in PubMed; PMID: 27185810.
- McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med 2010;7(6):557–570. doi:https://doi.org/10.1016/j.genm.2010.11.010. Cited in PubMed; PMID: 21195356.
- Mehta P, et al. Prevalence of amyotrophic lateral sclerosis - United States, 2012-2013. MMWR Surveill Summ 2016;65(8):1–12. doi:https://doi.org/10.15585/mmwr.ss6508a1. Cited in: PubMed; PMID: 27490513.
- Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377(9769):942–55. doi:https://doi.org/10.1016/s0140-6736(10)61156-7. Cited in: PubMed; PMID: 21296405.
- van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH. Amyotrophic lateral sclerosis. Lancet 2017;390(10107):2084–98. doi:https://doi.org/10.1016/S0140-6736(17)31287-4. Cited in: PubMed; PMID: 28552366.
- Grad LI, Rouleau GA, Ravits J, Cashman NR. Clinical spectrum of amyotrophic lateral sclerosis (ALS). Cold Spring Harb Perspect Med 2017;7(8):1–16. doi:https://doi.org/10.1101/cshperspect.a024117. Cited in: PubMed; PMID: 28003278.
- Turner MR, Scaber J, Goodfellow JA, Lord ME, Marsden R, Talbot K. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J Neurol Sci 2010;294(1-2):81–5. doi:https://doi.org/10.1016/j.jns.2010.03.028. Cited in: PubMed; PMID: 20452624.
- United States Food and Drug Administration. FDA approves drug to treat ALS [FDA news release]. Washington (DC): Food and Drug Administration.gov; 2017 May 5. https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-als.
- Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;3:CD001447. doi:https://doi.org/10.1002/14651858.CD001447.pub3. Cited in: PubMed; PMID: 22419278.
- Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr 2018;62(1):20–38. doi:https://doi.org/10.3164/jcbn.17-62. Cited in: PubMed; PMID: 29371752.
- Thakore-James M, Salajegheh M, James N. Retrospective review of respiratory function in the amyotrophic lateral sclerosis (ALS) veteran population with and without edaravone therapy. Neurology 2019;92(15 supplement). S54.009 ISSN 0028-3878. Cited in: Neurology.
- Harrison D, et al. ALS reversals: demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degener 2018;19(7-8):495–9. doi:https://doi.org/10.1080/21678421.2018.1457059.
- Tsai CP, Ho HH, Yen DJ, Wang V, Lin KP, Liao KK, Wu ZA. Reversible motor neuron disease. Eur Neurol 1993;33:387–9. doi:https://doi.org/10.1159/000116977.
- Bedlack RS, et al. How common are ALS plateaus and reversals? Neurology 2016;86(9):808–12. doi:https://doi.org/10.1212/WNL.0000000000002251.
- Chandrasoma B, Balfe D, Naik T, Elsayegh A, Lewis M, Mosenifar Z. Pulmonary function in patients with amyotrophic lateral sclerosis at disease onset. Monaldi Arch Chest Dis 2012;77(3-4):129–33. doi:https://doi.org/10.4081/monaldi.2012.146.